Clinical Research Directory
Browse clinical research sites, groups, and studies.
Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer
Sponsor: Peking Union Medical College Hospital
Summary
Due to dMMR colon cancer patients respond poorly to conventional chemotherapy, but immunotherapy can significantly improve the pCR in this group of patients, this study intends to explore whether neoadjuvant immunotherapy can improve the R0 resection rate with preservation of adjacent organs in T4 colon cancer patients with dMMR.
Official title: Efficacy of Neoadjuvant Immunotherapy for T4 Deficient Mismatch Repair (dMMR) Colon Cancer: A Prospective, Single-arm, Phase Ⅱ Clinical Trial
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2024-01-01
Completion Date
2030-02-10
Last Updated
2025-09-05
Healthy Volunteers
No
Interventions
Camrelizumab
Camrelizumab 200mg for 3 cycles. Patients will undergo surgery 2-3 weeks after the last cycle of immunotherapy, type and extent of the surgery will be selected by the surgeon.
Locations (2)
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital
Beijing, China